Catabasis has announced that their trial of edasalonexent is now open at 2 centres in the UK. Sites in Bristol and Manchester are recruiting and two …
Catabasis opens new UK sites in Edasalonexent trialRead More
Wave announces trial results and new trial plans
Wave Life Sciences have today announced the results of their early stage phase 1 clinical trial of Suvodirsen, as well as their plans for a much …
Department for Transport Meeting
Yesterday our CEO, Shelley, was invited to the House of Commons to meet with the Secretary-under-State for the Department of Transport, Nusrat Ghani …
Santhera announces plans to apply for conditional approval for Puldysa
Santhera Pharmaceuticals has announced plans to submit an application for Conditional Approval for Puldysa (also known as idebenone and Raxone) for …
Santhera announces plans to apply for conditional approval for PuldysaRead More
Sarepta Therapeutics announces preliminary results in casimersen (exon 45 skipping) trial
In a press release earlier, Sarepta Therapeutics announced results of an interim analysis of the casimersen part of their late stage, phase 3 ESSENCE …
Sarepta Therapeutics announces preliminary results in casimersen (exon 45 skipping) trialRead More
Study investigates bone health in Duchenne
A recently published study has found that boys treated with daily Deflazacort (a corticosteroid) have more fractures than boys treated with other …
Annemeike standards of care video news article
Progression of time – Benjamin James
Taken from Benjamin James' blog HorizonsofHope - living with a neuromuscular condition, feelings, frustrations and hope. "Recently I have …
Dave’s story
Fundraiser profile Dave Hampton Age 52 Devoted Husband & Father …
Raxone: A Guide for the Community
Raxone (also known as Idebenone) is a drug produced by Santhera Pharmaceuticals, which treats several conditions and has the potential to treat …
Santhera announces idebenone study results
In a press release, Santhera Pharmaceuticals has announced results from the SYROS study, where long-term treatment with idebenone (also known as …
Duchenne Parent Project International Conference
This weekend our Director of Research, Neil Bennett, and our CEO, Shelley Simmonds, are in Rome attending the Duchenne Parent Project International …
